Financial PerformancePulmonx reported a relatively in-line first quarter, with revenue of $22.5M (+20.7% Y/Y CC), slightly ahead of our $22.3M estimate and the consensus of $22.0M.
Growth InitiativesThe 'acquire, test, treat' strategy, including initiatives to increase funnel interest and reduce patient fallout, is expected to drive growth acceleration.
Product LaunchLungTrax platform is in full launch, with some hospitals already seeing increased throughput and reduced time-to-procedure.